Funding Details
- Awarder
- Inbox
- Date Award
- April 28, 2022
- Vertical
- Biotechnology
- Funding URL
- View Funding Page
Company Info
- Founders
- Kannan Rangaramanujam, Sujatha Kannan
- Company Description
- Ashvattha Therapeutics is a clinical-stage biotech company developing novel hydroxyl dendrimer therapeutics (HDTs) targeting unmet medical needs in ophthalmology, neurology, inflammation and neuro-oncology. The therapies are based on hydroxyl dendrimers (HDs), a targeted platform technology exclusively licensed from firm founders, Kannan Rangaramanujam and Sujatha Kannan at Johns Hopkins University.
- Market
- Ophthalmology, Neurology, Inflammation, Neuro-oncology
- Coinvestors
- Huadong Medicine Investment Holding Co., Natural Capital, Plum Alley Investments, Tribe Capital
Links